Christopher Peetz - 03 Feb 2025 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Reporting relationship: CHIEF EXECUTIVE OFFICER, Director
Issuer ticker: MIRM
Reported as of: 03 Feb 2025
Net transaction value: -$438,921
SEC form: 4
Accepted by SEC: 04 Feb 2025, 17:30:12 UTC
Prior SEC filing: 27 Jan 2025
Next SEC filing: 04 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ Judit Ryvkin, Attorney-in-Fact

Key filing fact

Christopher Peetz filed Form 4 for Mirum Pharmaceuticals, Inc. (MIRM) on 04 Feb 2025.

Key facts

This page summarizes Christopher Peetz's Form 4 filing for Mirum Pharmaceuticals, Inc. (MIRM).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 04 Feb 2025, 17:30.

Change

Previous filing in this sequence was filed on 27 Jan 2025.
Current net transaction value: -$438,921.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MIRM transaction

Common Stock

Sale

Transaction value: $438,921
Shares: -9,102
Change %: -7.3%
Price: $48.22
Shares after: 115,920
Date: 03 Feb 2025
Ownership: Direct
Footnotes: F1

MIRM holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 208,570
Date: 03 Feb 2025
Ownership: By The Peetz Family Trust

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .